Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Nonmyeloablative
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Denmark
100%
Population-based Study
100%
Myelofibrosis
100%
Non-relapse Mortality
66%
Hazard Ratio
66%
Myeloablative Conditioning
55%
Day Range
33%
Overall Survival
33%
Myeloablative Regimen
33%
Hematopoietic Stem Cell Transplantation
22%
Annualized Relapse Rate
22%
Multivariable
22%
Reduced-intensity Conditioning
22%
Fludarabine
22%
Male Sex
22%
Unrelated Donor
22%
Grafting from
22%
Comorbidity Index
22%
Follow-up Time
11%
Transplant Outcomes
11%
Independency
11%
Copenhagen
11%
Transfusion
11%
Conditioning Regimen
11%
Neutrophil Engraftment
11%
Platelet Engraftment
11%
Patient Comorbidities
11%
University Hospital
11%
Retrospective Cohort Study
11%
Transplant Center
11%
Early Relapse
11%
Relapse Rate
11%
Conditioning Intensity
11%
Patient Sex
11%
Karnofsky Performance Status
11%
Total Body Irradiation
11%
NRAS mutation
11%
Median Time
11%
Comorbidity Burden
11%
Progression-free Survival
11%
Survival Analysis
11%
Patient Relationships
11%
Low-dose Irradiation
11%
Young Patients
11%
Primary Graft Failure
11%
Fit Patients
11%
Medicine and Dentistry
Myelofibrosis
100%
Allogeneic Hematopoietic Stem Cell Transplantation
100%
Non-Relapse Mortality
66%
Hazard Ratio
66%
Comorbidity
33%
Overall Survival
33%
Nonmyeloablative Conditioning
33%
Myeloablative Conditioning
22%
Engraftment
22%
Fludarabine
22%
Cumulative Incidence
22%
Reduced Intensity Conditioning
22%
Hematopoietic Stem Cell Transplantation
22%
Whole Body Radiation
22%
Karnofsky Performance Status
11%
Neutrophil
11%
Low Drug Dose
11%
Graft Failure
11%
Survival Analysis
11%
Independency
11%
Retrospective Cohort Study
11%
Recurrence Risk
11%
Progression Free Survival
11%
Platelet
11%
Independent Factor
11%
Median Follow Up
11%
Immunology and Microbiology
Allogeneic Hematopoietic Stem Cell Transplantation
100%
Comorbidity
37%
Overall Survival
37%
Hematopoietic Stem Cell Transplantation
25%
Engraftment
25%
Platelet
12%
Neutrophil
12%
Independency
12%
Low Drug Dose
12%
Progression Free Survival
12%